G1 Therapeutics Inc (NASDAQ:GTHX) has been assigned a consensus recommendation of “Buy” from the eight analysts that are covering the firm, MarketBeat Ratings reports. Two investment analysts have rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $74.50.
GTHX has been the subject of several analyst reports. Needham & Company LLC increased their price objective on G1 Therapeutics to $76.00 and gave the stock a “buy” rating in a research report on Tuesday, September 18th. HC Wainwright restated a “buy” rating and set a $79.00 price target on shares of G1 Therapeutics in a research note on Monday, September 17th. BTIG Research initiated coverage on G1 Therapeutics in a research note on Monday, September 10th. They set a “buy” rating and a $80.00 price target on the stock. Cowen restated a “buy” rating on shares of G1 Therapeutics in a research note on Thursday, August 9th. Finally, JPMorgan Chase & Co. upped their price target on G1 Therapeutics from $58.00 to $63.00 and gave the stock an “overweight” rating in a research note on Friday, August 10th.
G1 Therapeutics stock traded down $0.09 during mid-day trading on Monday, hitting $46.81. The company’s stock had a trading volume of 392,853 shares, compared to its average volume of 347,635. The firm has a market capitalization of $1.57 billion, a price-to-earnings ratio of -13.11 and a beta of -1.06. G1 Therapeutics has a 1 year low of $18.03 and a 1 year high of $69.57.
G1 Therapeutics (NASDAQ:GTHX) last issued its quarterly earnings data on Wednesday, August 8th. The company reported ($0.64) earnings per share for the quarter, topping the consensus estimate of ($0.65) by $0.01. Equities research analysts predict that G1 Therapeutics will post -2.66 earnings per share for the current fiscal year.
In other G1 Therapeutics news, insider Rajesh Malik sold 3,776 shares of the company’s stock in a transaction on Monday, September 17th. The stock was sold at an average price of $66.08, for a total transaction of $249,518.08. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider Mark A. Velleca sold 5,000 shares of the stock in a transaction on Monday, October 15th. The shares were sold at an average price of $41.53, for a total value of $207,650.00. The disclosure for this sale can be found here. Insiders have sold 66,583 shares of company stock worth $3,614,546 over the last 90 days. 15.92% of the stock is owned by insiders.
Several hedge funds and other institutional investors have recently made changes to their positions in GTHX. Bank of New York Mellon Corp raised its stake in shares of G1 Therapeutics by 1,497.7% in the second quarter. Bank of New York Mellon Corp now owns 1,262,991 shares of the company’s stock valued at $54,890,000 after acquiring an additional 1,183,940 shares in the last quarter. BlackRock Inc. increased its holdings in G1 Therapeutics by 71.9% in the first quarter. BlackRock Inc. now owns 1,281,060 shares of the company’s stock valued at $47,463,000 after buying an additional 535,615 shares during the last quarter. Voya Investment Management LLC increased its holdings in G1 Therapeutics by 7,889.9% in the second quarter. Voya Investment Management LLC now owns 449,834 shares of the company’s stock valued at $19,550,000 after buying an additional 444,204 shares during the last quarter. BB Biotech AG purchased a new position in G1 Therapeutics in the second quarter valued at $15,324,000. Finally, JPMorgan Chase & Co. increased its holdings in G1 Therapeutics by 1,313.5% in the first quarter. JPMorgan Chase & Co. now owns 221,555 shares of the company’s stock valued at $8,209,000 after buying an additional 205,881 shares during the last quarter. Institutional investors and hedge funds own 69.17% of the company’s stock.
G1 Therapeutics Company Profile
G1 Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel small molecule therapeutics for the treatment of patients with cancer in the United States. It is developing trilaciclib, an intravenous cyclin-dependent kinases (CDK) 4/6 inhibitor that is in Phase 1b/2a clinical trials for patients with small cell lung cancer, as well as Phase 2 clinical trial for patients with first-/second-/third-line metastatic triple-negative breast cancer; G1T38, an oral CDK4/6 inhibitor that is Phase 1b/2a clinical trials for the treatment of breast cancer; and G1T48, an oral selective estrogen receptor degrader, which is in preclinical development.
See Also: Penny Stocks, Risk and Reward Factors
Receive News & Ratings for G1 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for G1 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.